24 related articles for article (PubMed ID: 10608349)
1. Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigen.
Nowak J; Cohen EP; Graf LH
Cancer Immunol Immunother; 1991; 33(2):91-6. PubMed ID: 1674672
[TBL] [Abstract][Full Text] [Related]
2. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from cancer vaccine trials and target antigen choice.
Butterfield LH
Cancer Immunol Immunother; 2016 Jul; 65(7):805-12. PubMed ID: 26842127
[TBL] [Abstract][Full Text] [Related]
4. GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma.
Piñón-Zárate G; Herrera-Enríquez MÁ; Hernández-Téllez B; Jarquín-Yáñez K; Castell-Rodríguez AE
J Immunol Res; 2014; 2014():158980. PubMed ID: 25759825
[TBL] [Abstract][Full Text] [Related]
5. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.
Blalock LT; Landsberg J; Messmer M; Shi J; Pardee AD; Haskell R; Vujanovic L; Kirkwood JM; Butterfield LH
Oncoimmunology; 2012 May; 1(3):287-357. PubMed ID: 22737604
[TBL] [Abstract][Full Text] [Related]
6. New approaches to the development of adenoviral dendritic cell vaccines in melanoma.
Butterfield LH; Vujanovic L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1399-408. PubMed ID: 21154122
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.
Prins RM; Shu CJ; Radu CG; Vo DD; Khan-Farooqi H; Soto H; Yang MY; Lin MS; Shelly S; Witte ON; Ribas A; Liau LM
Cancer Immunol Immunother; 2008 Sep; 57(9):1279-89. PubMed ID: 18253732
[TBL] [Abstract][Full Text] [Related]
9. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.
Adam C; Mysliwietz J; Mocikat R
J Transl Med; 2007 Mar; 5():16. PubMed ID: 17359532
[TBL] [Abstract][Full Text] [Related]
10. Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells.
Zhang J; Zhang JK; Zhuo SH; Chen HB
World J Gastroenterol; 2001 Oct; 7(5):690-4. PubMed ID: 11819855
[TBL] [Abstract][Full Text] [Related]
11. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B
Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054
[TBL] [Abstract][Full Text] [Related]
12. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
13. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687
[TBL] [Abstract][Full Text] [Related]
14. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.
Ribas A; Butterfield LH; McBride WH; Dissette VB; Koh A; Vollmer CM; Hu B; Chen AY; Glaspy JA; Economou JS
Cancer Gene Ther; 1999; 6(6):523-36. PubMed ID: 10608349
[TBL] [Abstract][Full Text] [Related]
15. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.
Ribas A; Butterfield LH; McBride WH; Jilani SM; Bui LA; Vollmer CM; Lau R; Dissette VB; Hu B; Chen AY; Glaspy JA; Economou JS
Cancer Res; 1997 Jul; 57(14):2865-9. PubMed ID: 9230191
[TBL] [Abstract][Full Text] [Related]
16. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
